Drug-induced heart failure.
Am J Health Syst Pharm. 2011 Oct 1;68(19):1791-804
Authors: Maxwell CB, Jenkins AT
Abstract
Purpose The published evidence on the role of various drugs and medication classes in caus…

[Read more →]

Effect of fondaparinux prophylaxis on anti-factor Xa concentrations in patients with morbid obesity.
Am J Health Syst Pharm. 2011 Sep 15;68(18):1716-22
Authors: Martinez L, Burnett A, Borrego M, Streeter JC, Townsend K, Garcia…

[Read more →]

Development and implementation of an interdisciplinary oncology program in a community hospital.
Am J Health Syst Pharm. 2011 Sep 15;68(18):1740-7
Authors: Chung C, Collins A, Cui N
Abstract
Purpose The develop…

[Read more →]

Dabigatran etexilate: A novel oral direct thrombin inhibitor.
Am J Health Syst Pharm. 2011 Aug 15;68(16):1506-19
Authors: Blommel ML, Blommel AL
Purpose The pharmacology, pharmacokinetics, clinical efficacy, tolerabili…

[Read more →]

Anticoagulation therapy for hospitalized patients: Patterns of use, compliance with national guidelines, and performance on quality measures.
Am J Health Syst Pharm. 2011 Jul 1;68(13):1239-44
Authors: Tiryaki F, Nutescu EA, He…

[Read more →]

Management of HIV infection in treatment-naive patients: A review of the most current recommendations.
Am J Health Syst Pharm. 2011 Jun 1;68(11):991-1001
Authors: Boyd SD
Purpose The most current guidelines issued by t…

[Read more →]

Effect of early clopidogrel discontinuation on rehospitalization in acute coronary syndrome: Results from two distinct patient populations.
Am J Health Syst Pharm. 2011 Jun 1;68(11):1015-24
Authors: Ernst FR, Johnston S, Curke…

[Read more →]

Effect of bar-code-assisted medication administration on nurses’ activities in an intensive care unit: A time-motion study.
Am J Health Syst Pharm. 2011 Jun 1;68(11):1026-31
Authors: Dwibedi N, Sansgiry SS, Frost CP, Dasgupta …

[Read more →]

Iron replacement therapy in cancer-related anemia.
Am J Health Syst Pharm. 2011 May 15;68(10 Suppl 1):S4-S14
Authors: Baribeault D, Auerbach M
Purpose The incidence, etiology, and management of cancer-related anemia is…

[Read more →]

Nebivolol for the treatment of heart failure.
Am J Health Syst Pharm. 2011 May 15;68(10):879-86
Authors: Dery AS, Hamilton LA, Starr JA
Purpose The pharmacology, pharmacokinetics, efficacy, safety, and place in therapy…

[Read more →]

Substitution of a heparin correlation value for activated partial thromboplastin time in heparin nomograms.
Am J Health Syst Pharm. 2011 May 15;68(10):893-8
Authors: Miller AE, Montague D, Rodgers JE, Sanghvi S, Whinna HC, Kru…

[Read more →]

Effect of a pharmacist-managed culture review process on antimicrobial therapy in an emergency department.
Am J Health Syst Pharm. 2011 May 15;68(10):916-9
Authors: Randolph TC, Parker A, Meyer L, Zeina R
Purpose The i…

[Read more →]

Development and implementation of a pharmacist-managed inpatient anticoagulation monitoring program.
Am J Health Syst Pharm. 2011 May 15;68(10):934-9
Authors: Wellman JC, Kraus PS, Burton BL, Ensor CR, Nesbit TW, Ross PA, Thom…

[Read more →]

Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.
Am J Health Syst Pharm. 2011 May 1;68(9):818-27
Authors: Koren MJ, Hamad A, Klasen S, Abeyratne A, McNutt BE, Kalra S
…

[Read more →]

Ceftaroline: A new broad-spectrum cephalosporin.

Am J Health Syst Pharm. 2011 Mar 15;68(6):491-8

Authors: Lim L, Sutton E, Brown J

Purpose The pharmacokinetics, pharmacodynamics, clinical efficacy, and safety of ceftaroline are reviewed. Summary Ceftaroline, a new broad- spectrum antibiotic, is approved for the treatment of complicated skin and skin structure infections (cSSSIs) and community- acquired pneumonia (CAP). This ?-lactam antibiotic has extended activity against gram-positive organisms and has activity against common gram-negative organisms. The drug’s spectrum of activity includes both methicillin-resistant Staphylococcus aureus and multidrug-resistant Streptococcus pneumoniae. However, its activity against extended-spectrum ?-lactamase-producing bacteria is limited. These bacteria, particularly those that express AmpC ?-lactamase, greatly reduce the activity of ceftaroline. The prodrug of ceftaroline (ceftaroline fosamil) is rapidly converted to its active form (ceftaroline) in plasma. This dose-linear drug has been found to be pharmacodynamically best correlated with the percentage of time that free drug concentrations remain above the minimum inhibitory concentration. Ceftaroline’s safety profile is similar to that of the other cephalosporins, with minimal adverse drug reactions, most of which are considered mild. Currently available pharmacokinetic, animal, and clinical studies have found that ceftaroline has reasonable efficacy and tolerability but have also revealed that dosing regimen modifications may be needed in patients with moderate-to-severe renal impairment. The recommended dosage of ceftaroline for the treatment of cSSSIs and CAP is 600 mg infused intravenously over 60 minutes every 12 hours. The recommended duration of therapy is 5-14 and 5-7 days for cSSSIs and CAP, respectively. Additional Phase III studies are currently underway. Conclusion Ceftaroline is a new broad-spectrum cephalosporin indicated for the treatment of cSSSIs and CAP caused by susceptible gram-positive and gram-negative organisms.

PMID: 21378297 [PubMed - in process]

[Read more →]